Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) — Medicare Part D spending
Multiple manufacturers (3) · Rank #130 by total Part D spend · CMS data year 2023
Medicare Part D spent $414,349,616 on Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) in 2023, the #130 drug by total Part D spending out of 3,598 drugs. That worked out to about $15.05 per dosage unit, $282 per claim and $893 per beneficiary, across 1,468,371 claims for 464,129 beneficiaries. Average spending per dosage unit rose +3.9% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) spending at a glance (2023)
| Metric | Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) |
|---|---|
| Total Part D spending (2023) | $414,349,616 |
| Total spending (2022) | $306,378,628 |
| Year-over-year change in total spending | +35.2% |
| Average spending per dosage unit (2023) | $15.05 |
| Change in spend per dosage unit (YoY) | +3.9% |
| Avg annual change per dosage unit (2019-2023 CAGR) | -1.3% |
| Average spending per claim (2023) | $282 |
| Average spending per beneficiary (2023) | $893 |
| Total claims (2023) | 1,468,371 |
| Beneficiaries (2023) | 464,129 |
| Total dosage units (2023) | 121,280,123 |
| Manufacturer(s) | Multiple manufacturers (3) |
| National rank by total spend (of 3,598 drugs) | #130 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $306,378,628 | $414,349,616 | +35.2% |
| Avg spend per dosage unit | $14.48 | $15.05 | +3.9% |
| Avg spend per claim | $250 | $282 | — |
| Avg spend per beneficiary | $808 | $893 | — |
| Total claims | 1,224,703 | 1,468,371 | — |
| Beneficiaries | 379,127 | 464,129 | — |
How Fluticasone-Salmeterol compares with nearby drugs
Drugs with total Part D spending closest to Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) (this drug, #130) | $414,349,616 | $15.05 | +3.9% |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) (#128) | $423,142,555 | $0.30 | +1.8% |
| Omeprazole (#129) | $422,372,715 | $0.20 | +3.4% |
| Kesimpta Pen (Ofatumumab) (#131) | $413,095,697 | $21,596.16 | +9.1% |
| Multaq (Dronedarone HCl) (#132) | $409,348,468 | $13.08 | +5.5% |
| Amlodipine Besylate (#133) | $407,233,375 | $0.12 | +12.9% |
Frequently asked questions
How much does Medicare Part D spend on Fluticasone-Salmeterol?
Medicare Part D spent $414,349,616 on Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) in 2023 (the latest CMS data year), across 1,468,371 claims for 464,129 beneficiaries. That ranks #130 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Fluticasone-Salmeterol?
In 2023, the weighted average Medicare Part D spending per dosage unit for Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) was $15.05. Compared with 2022 it rose +3.9%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Fluticasone-Salmeterol?
CMS attributes Fluticasone-Salmeterol (Fluticasone Propion/Salmeterol) to Multiple manufacturers (3) in the 2023 Part D spending file. Average spending per claim was $282 and per beneficiary $893.
Is the Fluticasone-Salmeterol figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20